A simple, selective, rapid, precise and economical reverse phase high pressure liquid chromatographic method has been developed for the simultaneous estimation of nebivolol and hydrochlorthiazide from pharmaceutical formulation. Phenomenex Gemini C18 (25 cm×4.6 mm i.d., 5 μ) column with a mobile phase consisting of acetonitrile: 50mM ammonium acetate (adjusted to pH 3.5 using orthophosphoric acid) (70:30 v/v) at a flow rate of 1.0 ml/min was used. Detection was carried out at 254 nm. Probenecid was used as an internal standard. The retention times of probenecid, nebivolol and hydrochlorthiazide were 13.05, 3.32 and 4.25 min, respectively. The developed method was validated in terms of accuracy, precision, linearity, limit of detection, limit of quantitation and solution stability. The proposed method can be used for the estimation of these drugs in combined dosage forms.

Coenzyme Q10 (CoQ10) is a lipid soluble, endogenous antioxidant present at highest levels in the heart followed by the kidney and liver. The reduced CoQ10 ubiquinol is well known for its chemical instability and low bioavailability. The present study was designed to synthesize ubiquinol acetate, which is more stable and biologically active, and further evaluate its safety and genotoxic potential. Synthesized ubiquinol acetate showed better stability than that of ubiquinol at the end of 3 months. In vitro genotoxicity studies (AMES test, in vitro micronucleus and chromosomal aberration) showed ubiquinol acetate as nongenotoxic with no clastogenic or aneugenic effects at high dose of 5000 and 62.5 μg/mL, respectively. In subchronic toxicity study, ubiquinol acetate was administered orally to Sprague Dawley rats at 150, 300, and 600 mg/kg/day for 90 days. No treatment related adverse effects were observed in males at 600 mg/kg/day; however, females showed treatment related increase in AST and ALT with small focal irregular white-yellow spots in liver on gross necropsy examination. Histopathological evaluation revealed hepatocellular necrosis in high dose females which was considered as adverse. Based on the results, the No-Observed-Adverse-Effect Level (NOAEL) of ubiquinol acetate in males and females was determined as 600 and 300 mg/kg/day, respectively.

No abstract

No abstract

Objective was to compare pharmacokinetic characteristics of Sustained-Release (SR) and Immediate-Release (IR) formulations of dextromethorphan hydrobromide following a single oral administration of test and reference formulations in fasting healthy male volunteers. A randomized, 3-way, crossover, bioequivalence study was conducted in 6 healthy male volunteers to compare dextromethorphan hydrobromide Sustained Release (SR) tablet as test and the Immediate Release (IR) as reference product. Blood samples were collected and plasma samples were determined by using validated HPLC method involving a solid phase extraction method. Pharmacokinetic parameters were calculated by non-compartmental analysis. C max of the sustained-release formulation was significantly lower than that of the marketed immediate-release. The T max of sustained-release formulation was significantly long-lasting than that of immediate release. These results are in line with the profile of a sustained-release drug. This was also evident by the lower elimination rate and higher t½ values. However, the bioavailability of sustained-release tablets remained the identical as that of immediate release tablets.